propranolol has been researched along with Acute Post-Traumatic Stress Disorder in 90 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The prevalence of PTSD, anxiety, and depression was similar in children who received propranolol acutely and those who did not." | 9.27 | Does Acute Propranolol Treatment Prevent Posttraumatic Stress Disorder, Anxiety, and Depression in Children with Burns? ( Herndon, DN; Holzer, CE; Humphries, HF; Meyer, WJ; Rosenberg, L; Rosenberg, M; Sharp, S; Thomas, CR, 2018) |
| "The prevalence of PTSD, anxiety, and depression was similar in children who received propranolol acutely and those who did not." | 5.27 | Does Acute Propranolol Treatment Prevent Posttraumatic Stress Disorder, Anxiety, and Depression in Children with Burns? ( Herndon, DN; Holzer, CE; Humphries, HF; Meyer, WJ; Rosenberg, L; Rosenberg, M; Sharp, S; Thomas, CR, 2018) |
| "Propranolol or a placebo was administered 90 min before a brief memory reactivation session, once a week for 6 consecutive weeks." | 3.01 | Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial. ( Birmes, P; Bourcier, A; Dupuch, L; El Hage, W; Jasse, L; Lamy, P; Roullet, P; Thalamas, C; Vaiva, G; Véry, E; Yrondi, A, 2021) |
| "Propranolol or placebo was administered 90 minutes before a brief memory reactivation session, once a week for 6 consecutive weeks." | 2.87 | Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial. ( Brunet, A; Liu, A; Pitman, RK; Saumier, D; Streiner, DL; Tremblay, J, 2018) |
| " However, a high level of heterogeneity, variation in propranolol dosage and inadequate sample sizes mean that these findings require cautious interpretation." | 2.82 | Effects of propranolol on the modification of trauma memory reconsolidation in PTSD patients: A systematic review and meta-analysis. ( Benedek, DM; Canales, JJ; Eri, R; Johnson, LR; Raut, SB; Ravindran, M; Ursano, RJ, 2022) |
| "Propranolol has effectively diminished fear-based emotional memories in posttraumatic stress disorder (PTSD) and this effect has been attributed to traumatic memory reconsolidation blockade." | 2.82 | Propranolol's impact on cognitive performance in post-traumatic stress disorder. ( Ashbaugh, AR; Mahabir, M; Saumier, D; Tremblay, J, 2016) |
| "Posttraumatic stress disorder (PTSD) may involve over-consolidated emotional memories of the traumatic event." | 2.80 | Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies. ( Fischer, AM; Goetz, JM; Lasko, NB; Marin, MF; Orr, SP; Pitman, RK; Rosasco, ML; Spring, JD; Suris, AM; Wood, NE, 2015) |
| "At 4 and 12 weeks post-trauma, PTSD symptoms were assessed." | 2.77 | Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery. ( Chang, Y; Feterowski, CM; Goetz, JM; Hoge, EA; Katzman, AR; Kay, EB; Lasko, NB; Nagurney, JT; Orr, SP; Pitman, RK; Pollack, MH; Rosasco, ML; Worthington, JJ; Zusman, RM, 2012) |
| "Six-week PTSD symptoms and heart rate were assessed." | 2.75 | The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: a pilot study. ( Browne, L; Christopher, NC; Crow, JP; Delahanty, DL; Nugent, NR; Ostrowski, S, 2010) |
| "Because PTSD has as prominent features heightened arousal and distressing memories, the current study was undertaken to examine whether PTSD subjects differed from controls in emotional enhancement of memory." | 2.70 | beta-Adrenergic blockade and emotional memory in PTSD. ( Cahill, L; Duffy, JG; Fujimoto, K; Reist, C, 2001) |
| "Also, when PTSD has already developed, chronic treatment with propranolol may be more effective than acute intervention, given that individuals with PTSD tend to experience long-term, elevated noradrenergic hyperarousal." | 2.53 | Revisiting propranolol and PTSD: Memory erasure or extinction enhancement? ( Fitzgerald, PJ; Giustino, TF; Maren, S, 2016) |
| "PTSD was diagnosed according to DSM or widely accepted and validated diagnostic tools." | 2.52 | Prevention of posttraumatic stress disorder with propranolol: A meta-analytic review. ( Argolo, FC; Cavalcanti-Ribeiro, P; Netto, LR; Quarantini, LC, 2015) |
| "Given the negative sequelae of trauma/PTSD, research has focused on identifying efficacious interventions that could be administered soon after a traumatic event to prevent or reduce the subsequent incidence of PTSD." | 2.50 | Pharmacological modulation of acute trauma memories to prevent PTSD: considerations from a developmental perspective. ( Cullen, PK; Delahanty, DL; Hruska, B, 2014) |
| "Post-traumatic stress disorder (PTSD) is a debilitating disorder which, after a sufficient delay, may be diagnosed amongst individuals who respond with intense fear, helplessness or horror to traumatic events." | 2.50 | Pharmacological interventions for preventing post-traumatic stress disorder (PTSD). ( Amos, T; Ipser, JC; Stein, DJ, 2014) |
| "Posttraumatic stress disorder (PTSD) is a serious mental health disorder." | 2.49 | Psychopharmacological treatment for military posttraumatic stress disorder: an integrative review. ( Murphy, S; Tawa, J, 2013) |
| "Post-traumatic stress disorder (PTSD) is increasingly recognized as a serious and potentially debilitating condition in combat veterans returning from Iraq and Afghanistan." | 2.47 | Novel combination strategy to optimize treatment for PTSD. ( North, CS; Shad, MU; Suris, AM, 2011) |
| "We also review the history of PTSD and the development of its diagnostic criteria." | 2.44 | Post-traumatic stress disorder and its treatment in children and adolescents. ( Najjar, F; Weisbrot, J; Weller, EB; Weller, RA, 2008) |
| "Atropine has also shown to disrupt memory formation." | 1.56 | Blockade of muscarinic receptors impairs reconsolidation of older fear memory by decreasing cholinergic neurotransmission: A study in rat model of PTSD. ( Batool, Z; Haider, S; Liaquat, L; Rafiq, S, 2020) |
| "Post-traumatic stress disorder (PTSD) is a common consequence of exposure to a life-threatening event." | 1.48 | Influence of early stress on memory reconsolidation: Implications for post-traumatic stress disorder treatment. ( Benkahoul, A; Birmes, P; Ferry, B; Roullet, P; Villain, H, 2018) |
| "Post-traumatic stress disorder (PTSD) is a learning-based anxiety disorder with significant public health challenges due to difficulties in treating the complex, multiple symptomology." | 1.48 | Propranolol produces short-term facilitation of extinction in a rabbit model of post-traumatic stress disorder. ( Burhans, LB; Schreurs, BG; Smith-Bell, CA, 2018) |
| "Posttraumatic stress disorder (PTSD) is often associated with acute panic, dissociation, suicidality, and aggression." | 1.46 | Serotonergic Synergy in the Pharmacotherapy of Acute Posttraumatic Stress Disorder Exacerbation: A Case Report. ( Guina, J; Pennington, JG, 2017) |
| "Twenty-eight participants with PTSD read an account of their traumatic event once weekly for 6 consecutive weeks under the influence of open-label propranolol." | 1.40 | Trauma reactivation plus propranolol is associated with durably low physiological responding during subsequent script-driven traumatic imagery. ( Ashbaugh, AR; Azzoug, A; Brunet, A; Orr, SP; Pitman, RK; Saumier, D; Thomas, É; Tremblay, J, 2014) |
| "Post-traumatic stress disorder (PTSD) is a common complication of an ICU admission." | 1.40 | Propranolol, post-traumatic stress disorder, and intensive care: incorporating new advances in psychiatry into the ICU. ( Gardner, AJ; Griffiths, J, 2014) |
| "Posttraumatic stress disorder (PTSD) is associated with enhanced noradrenergic activity." | 1.37 | Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats--a possible mechanism for the persistence of traumatic memories in PTSD. ( Bush, DE; Dębiec, J; LeDoux, JE, 2011) |
| "Propranolol was not found to influence the risk for subsequent ASD." | 1.36 | Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma. ( Meyer, W; Rosenberg, L; Rosenberg, M; Sharp, S; Thomas, C, 2010) |
| "Propranolol use has been examined in three phases of memory, including acquisition, formation, and encoding; emotional response and consolidation; and retrieval and reconsolidation." | 1.36 | Propranolol use in the prevention and treatment of posttraumatic stress disorder in military veterans: forgetting therapy revisited. ( Donovan, E, 2010) |
| "For severe cases of PTSD propranolol may help victims who don't respond to any other therapy or therapy combination regain their authentic self-narrative and engage once more in life activities." | 1.35 | Propranolol, post-traumatic stress disorder and narrative identity. ( Bell, J, 2008) |
| "This is surprising, given that PTSD is the mental disorder with the most clearly identified cause and onset." | 1.33 | Conceptually driven pharmacologic approaches to acute trauma. ( Delahanty, DL; Pitman, RK, 2005) |
| "The propranolol failed to produce any measurable effects on acquisition or retention of the CR and there was no evidence of increased conditionability in individuals diagnosed with PTSD." | 1.33 | Effects of beta blockade, PTSD diagnosis, and explicit threat on the extinction and retention of an aversively conditioned response. ( Gilbertson, MW; Lasko, NB; Metzger, LJ; Milad, MR; Orr, SP; Pitman, RK, 2006) |
| "Following a 6th accident, severe PTSD symptoms reemerged." | 1.31 | Propranolol for reemergent posttraumatic stress disorder following an event of retraumatization: a case study. ( Cahill, L; Taylor, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (4.44) | 18.7374 |
| 1990's | 2 (2.22) | 18.2507 |
| 2000's | 37 (41.11) | 29.6817 |
| 2010's | 38 (42.22) | 24.3611 |
| 2020's | 9 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mallet, C | 1 |
| Chick, CF | 1 |
| Maatoug, R | 1 |
| Fossati, P | 1 |
| Brunet, A | 9 |
| Millet, B | 1 |
| Raut, SB | 1 |
| Canales, JJ | 1 |
| Ravindran, M | 1 |
| Eri, R | 1 |
| Benedek, DM | 1 |
| Ursano, RJ | 1 |
| Johnson, LR | 1 |
| Szeleszczuk, Ł | 1 |
| Frączkowski, D | 1 |
| Laurin, A | 1 |
| Bulteau, S | 1 |
| Dumont, R | 1 |
| Sauvaget, A | 1 |
| Meister, L | 1 |
| Dietrich, AC | 1 |
| Stefanovic, M | 1 |
| Bavato, F | 1 |
| Rosi-Andersen, A | 1 |
| Rohde, J | 1 |
| Offenhammer, B | 1 |
| Seifritz, E | 1 |
| Schäfer, I | 1 |
| Ehring, T | 1 |
| Barth, J | 1 |
| Kleim, B | 1 |
| Rafiq, S | 1 |
| Batool, Z | 1 |
| Liaquat, L | 1 |
| Haider, S | 1 |
| Careaga, MBL | 1 |
| Girardi, CEN | 1 |
| Suchecki, D | 1 |
| Roullet, P | 2 |
| Vaiva, G | 2 |
| Véry, E | 1 |
| Bourcier, A | 1 |
| Yrondi, A | 1 |
| Dupuch, L | 1 |
| Lamy, P | 1 |
| Thalamas, C | 1 |
| Jasse, L | 1 |
| El Hage, W | 1 |
| Birmes, P | 3 |
| Rosenberg, L | 2 |
| Rosenberg, M | 2 |
| Sharp, S | 2 |
| Thomas, CR | 1 |
| Humphries, HF | 1 |
| Holzer, CE | 1 |
| Herndon, DN | 1 |
| Meyer, WJ | 1 |
| Saumier, D | 4 |
| Liu, A | 1 |
| Streiner, DL | 1 |
| Tremblay, J | 5 |
| Pitman, RK | 10 |
| Villain, H | 1 |
| Benkahoul, A | 1 |
| Ferry, B | 1 |
| Zhu, RT | 1 |
| Liu, XH | 1 |
| Shi, YW | 1 |
| Wang, XG | 1 |
| Xue, L | 1 |
| Zhao, H | 1 |
| Burhans, LB | 1 |
| Smith-Bell, CA | 1 |
| Schreurs, BG | 1 |
| Friedman, MJ | 1 |
| Rorabaugh, BR | 1 |
| Bui, AD | 1 |
| Seeley, SL | 1 |
| Eisenmann, ED | 1 |
| Rose, RM | 1 |
| Johnson, BL | 1 |
| Huntley, MR | 1 |
| Heikkila, ME | 1 |
| Zoladz, PR | 1 |
| Waits, WM | 1 |
| Hoge, CW | 1 |
| AlOkda, AM | 1 |
| Nasr, MM | 1 |
| Amin, SN | 1 |
| Kamboj, SK | 1 |
| Gong, AT | 1 |
| Sim, Z | 1 |
| Rashid, AA | 1 |
| Baba, A | 1 |
| Iskandar, G | 1 |
| Das, RK | 1 |
| Curran, HV | 1 |
| Kühlmeyer, K | 1 |
| Jox, RJ | 1 |
| Tawa, J | 1 |
| Murphy, S | 1 |
| Chandler, JA | 1 |
| Mogyoros, A | 1 |
| Rubio, TM | 1 |
| Racine, E | 1 |
| Hruska, B | 1 |
| Cullen, PK | 1 |
| Delahanty, DL | 3 |
| Amos, T | 1 |
| Stein, DJ | 1 |
| Ipser, JC | 1 |
| Thomas, É | 2 |
| Ashbaugh, AR | 2 |
| Azzoug, A | 2 |
| Orr, SP | 7 |
| Wood, NE | 1 |
| Rosasco, ML | 2 |
| Suris, AM | 2 |
| Spring, JD | 1 |
| Marin, MF | 1 |
| Lasko, NB | 4 |
| Goetz, JM | 2 |
| Fischer, AM | 1 |
| Gardner, AJ | 1 |
| Griffiths, J | 1 |
| Argolo, FC | 1 |
| Cavalcanti-Ribeiro, P | 1 |
| Netto, LR | 1 |
| Quarantini, LC | 1 |
| Roque, AP | 1 |
| Mahabir, M | 2 |
| Tucholka, A | 1 |
| Shin, LM | 1 |
| Etienne, P | 1 |
| Giustino, TF | 1 |
| Fitzgerald, PJ | 1 |
| Maren, S | 1 |
| Ronzoni, G | 1 |
| Del Arco, A | 1 |
| Mora, F | 1 |
| Segovia, G | 1 |
| Pennington, JG | 1 |
| Guina, J | 1 |
| Levy, N | 1 |
| Clarke, S | 1 |
| Bell, J | 1 |
| Cukor, J | 1 |
| Spitalnick, J | 1 |
| Difede, J | 1 |
| Rizzo, A | 1 |
| Rothbaum, BO | 1 |
| Thomas, C | 1 |
| Meyer, W | 1 |
| Donovan, E | 1 |
| Nugent, NR | 1 |
| Christopher, NC | 1 |
| Crow, JP | 1 |
| Browne, L | 1 |
| Ostrowski, S | 1 |
| Fletcher, S | 1 |
| Creamer, M | 1 |
| Forbes, D | 1 |
| Cohen, H | 1 |
| Kaplan, Z | 1 |
| Koresh, O | 1 |
| Matar, MA | 1 |
| Geva, AB | 1 |
| Zohar, J | 1 |
| Shad, MU | 1 |
| North, CS | 1 |
| Bryant, RA | 1 |
| Dębiec, J | 3 |
| Bush, DE | 1 |
| LeDoux, JE | 2 |
| Poundja, J | 1 |
| Bui, E | 1 |
| Hoge, EA | 1 |
| Worthington, JJ | 1 |
| Nagurney, JT | 1 |
| Chang, Y | 1 |
| Kay, EB | 1 |
| Feterowski, CM | 1 |
| Katzman, AR | 1 |
| Zusman, RM | 2 |
| Pollack, MH | 1 |
| Menzies, RP | 1 |
| Willyard, C | 1 |
| Aykaç, A | 1 |
| Aydın, B | 1 |
| Cabadak, H | 1 |
| Gören, MZ | 1 |
| Flaskerud, JH | 1 |
| Taylor, F | 1 |
| Cahill, L | 3 |
| Ducrocq, F | 1 |
| Jezequel, K | 1 |
| Averland, B | 1 |
| Lestavel, P | 1 |
| Marmar, CR | 1 |
| Miller, G | 1 |
| Giles, J | 1 |
| Glannon, W | 1 |
| Milad, MR | 1 |
| Metzger, LJ | 1 |
| Gilbertson, MW | 1 |
| Altemus, M | 1 |
| Adamec, R | 1 |
| Muir, C | 1 |
| Grimes, M | 1 |
| Pearcey, K | 1 |
| Strawn, JR | 1 |
| Geracioti, TD | 1 |
| Evers, K | 1 |
| Paquette, M | 1 |
| Robertson, K | 1 |
| Nader, K | 1 |
| Henry, M | 2 |
| Fishman, JR | 2 |
| Youngner, SJ | 2 |
| Trachtman, H | 1 |
| Hall, W | 1 |
| Carter, A | 1 |
| Kolber, A | 1 |
| Rosenberg, LB | 1 |
| Bell, JA | 1 |
| Craigie, J | 1 |
| Kabasenche, WP | 1 |
| Hurley, EA | 1 |
| Warnick, JE | 1 |
| Liao, SM | 1 |
| Wasserman, DT | 1 |
| Tenenbaum, EM | 1 |
| Reese, B | 1 |
| Sade, RM | 1 |
| Stein, MB | 1 |
| Kerridge, C | 1 |
| Dimsdale, JE | 1 |
| Hoyt, DB | 1 |
| Najjar, F | 1 |
| Weller, RA | 1 |
| Weisbrot, J | 1 |
| Weller, EB | 1 |
| van der Kolk, BA | 1 |
| Meerson, FZ | 1 |
| Pshennikova, MG | 1 |
| Rysmendiev, AZh | 1 |
| Vorontsova, EIa | 1 |
| Gillette, DW | 1 |
| Tannery, LP | 1 |
| Larkin, M | 1 |
| Reist, C | 1 |
| Duffy, JG | 1 |
| Fujimoto, K | 1 |
| Sanders, KM | 1 |
| Healy, AR | 1 |
| Cheema, F | 1 |
| Adler, L | 1 |
| Duncan, E | 1 |
| Angrist, B | 1 |
| Hemdal, P | 1 |
| Rotrosen, J | 1 |
| Slotnick, V | 1 |
| Famularo, R | 1 |
| Kinscherff, R | 1 |
| Fenton, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Using Reconsolidation Blockade to Treat Trauma Related Disorders After Paris Attacks: an Effectiveness Study[NCT02789982] | Phase 3 | 364 participants (Actual) | Interventional | 2016-05-27 | Completed | ||
| Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol: A Randomized Placebo-controlled Trial. PPP[NCT04985344] | Phase 3 | 92 participants (Anticipated) | Interventional | 2023-02-01 | Recruiting | ||
| Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial[NCT01713556] | Phase 2 | 87 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD[NCT04468360] | Phase 2 | 256 participants (Anticipated) | Interventional | 2022-03-04 | Recruiting | ||
| Comparing Standard vs. Modified Reconsolidation Blockade for the Treatment of Psychological Trauma: A Randomized Controlled Trial[NCT04982211] | Phase 2 | 150 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| A Novel Treatment For Chronic Posttraumatic Stress Disorder (PTSD) Using Post-Reactivation Propranolol[NCT01127568] | Phase 2/Phase 3 | 50 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol[NCT00709735] | Phase 4 | 23 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Developing Memory Reconsolidation Blockers as Novel PTSD Treatments[NCT01490697] | Phase 4 | 34 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Protocol for a Controlled Trial of Early Intervention With Children and Adolescents Exposed to Nonrelational Traumatic Events Comparing Trauma-informed and Usual Health Care Practice[NCT02299583] | 684 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | |||
| Psychological First Aid: A Randomized-controlled Trial of Adults Affected by Non-intentional Trauma in the Emergency Room[NCT02608086] | 220 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Prophylaxis of Posttraumatic Stress Disorder With Post-Trauma Propranolol[NCT00158262] | Phase 4 | 43 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Reliving the Traumatic Event in Posttraumatic Stress Disorder: An Emotional Memory Reactivation Pathology? An fMRI Study[NCT01239173] | Phase 3 | 5 participants (Actual) | Interventional | 2010-09-30 | Terminated (stopped due to Study stopped by promoter for lack of inclusion) | ||
| Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence[NCT00916721] | Phase 3 | 113 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Beta-Blockers and Inflammatory Responses to Acute Psychosocial Stress[NCT02972554] | Phase 4 | 92 participants (Actual) | Interventional | 2016-01-26 | Completed | ||
| Reduction of the Traumatic Memory by Reconsolidation Blockade: A Pilot Study[NCT00465608] | Phase 2 | 20 participants (Anticipated) | Interventional | 2007-04-30 | Completed | ||
| Propranolol Treatment of Traumatic Memories (PTTM)[NCT01069159] | 66 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | |||
| Reduction of the Reconsolidation of the Trauma Memory With Propranolol[NCT01349439] | Phase 2 | 76 participants (Anticipated) | Interventional | 2011-03-31 | Recruiting | ||
| Effects of Propranolol on Fear of Dental Extraction: Study Protocol for a Randomized Placebo-controlled Trial.[NCT02268357] | Phase 2/Phase 3 | 36 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Prevention of PTSD With Early Hydrocortisone Treatment: Pilot[NCT00597857] | 65 participants (Anticipated) | Interventional | 2005-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The posterior probability of developing PTSD was determined for each participant from a composite of psychophysiological responses during script-driven imagery of traumatic combat events that included assessments of heart rate response in beats per minute, skin conductance response in microSiemens, and corrugator and left lateral frontalis facial muscle electromyogram (EMG) responses in microVolts. Responses for the two traumatic scripts were averaged and square-root transformed for analysis. Responses during personal traumatic imagery of previously studied individuals with and without current PTSD was used to calculate each participant's posterior probability of being classified as PTSD. (NCT00709735)
Timeframe: Day 8
| Intervention | percent probability (Mean) |
|---|---|
| Non-Reactivation Propranolol (NRP) | 32 |
| Reactivation Propranolol (RP) | 45 |
IES-R is a 22-item patient reported measure of PTSD symptoms. Each question is answered using a 5-point scale where 0=not at all to 4=extremely for a total possible score of 0 to 88. Lower scores represent less severe symptoms and higher scores representing more severe symptoms. IES-R change scores were calculated by subtracting the Day 2 IES-R total score from the Day 8 IES-R total score. A negative change from Baseline indicates improvement of symptoms and a positive change from Baseline indicates a worsening of symptoms. (NCT00709735)
Timeframe: Day 2 (Baseline ) and Day 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 8 | |
| Non-Reactivation Propranolol (NRP) | 43.3 | -8.2 |
| Reactivation Propranolol (RP) | 45.0 | 4.5 |
The posterior probability of developing PTSD was determined for each participant from a composite of psychophysiological responses to script-driven imagery of traumatic events that included assessments of heart rate response in beats per minute, skin conductance response in microSiemens, and corrugator electromyogram (EMG) responses of the left lateral frontalis facial muscle in microVolts. Responses for the traumatic scripts were averaged and square-root transformed for analysis. Responses during personal traumatic imagery of previously studied individuals with and without current PTSD was used to calculate each participant's posterior probability of being classified as PTSD. (NCT01490697)
Timeframe: 1 week following treatment (Day 14)
| Intervention | percent probability (Mean) |
|---|---|
| Placebo Plus Placebo | 44 |
| Mifepristone Plus d-Cycloserine (DCS) | 45 |
IES-R is a 22-item patient reported measure of PTSD symptoms. Each question is answered using a 5-point scale where 0=not at all to 4=extremely for a total possible score of 0 to 88. Lower scores represent less severe symptoms and higher scores representing more severe symptoms. IES-R change scores were calculated by subtracting the Day 14 IES-R total score from the Day 7 IES-R total score. A negative change from Baseline indicates improvement of symptoms and a positive change from Baseline indicates a worsening of symptoms. (NCT01490697)
Timeframe: Day 7 (Baseline) and Day 14
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 14 | |
| Mifepristone Plus d-Cycloserine (DCS) | 52.4 | -8.9 |
| Placebo Plus Placebo | 55.3 | -5.0 |
The posterior probability of developing PTSD was determined for each participant from a composite of psychophysiological responses during script-driven mental imagery of traumatic events (two exemplars) that included assessments of heart rate response in beats per minute, skin conductance response in microSiemens, and corrugator and left lateral frontalis facial muscle electromyogram (EMG) responses in microVolts. Responses for the two traumatic scripts were averaged and square-root transformed for analysis. Responses during personal traumatic imagery of previously studied individuals with and without current PTSD were used to calculate each participant's posterior probability of being classified as PTSD. (NCT00158262)
Timeframe: Month 1
| Intervention | percent probability (Mean) |
|---|---|
| Placebo | 40.7 |
| Propranolol | 33.7 |
The posterior probability of developing PTSD was determined for each participant from a composite of psychophysiological responses during script-driven mental imagery of traumatic events (two exemplars) that included assessments of heart rate response in beats per minute, skin conductance response in microSiemens, and corrugator and left lateral frontalis facial muscle electromyogram (EMG) responses in microVolts. Responses for the two traumatic scripts were averaged and square-root transformed for analysis. Responses during personal traumatic imagery of previously studied individuals with and without current PTSD were used to calculate each participant's posterior probability of being classified as PTSD. (NCT00158262)
Timeframe: Month 3
| Intervention | percent probability (Mean) |
|---|---|
| Placebo | 34.9 |
| Propranolol | 32.0 |
The clinician evaluated the overall frequency and intensity/severity of the participant's PTSD symptoms using the CAPS. 17 Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) PTSD symptoms were assessed using a 5-point scale for intensity where 0=none to 4=extreme and a 5-point scale for frequency where 0=never to 4=most or all of the time. The intensity score and the frequency scores were added together for a total possible score of 0 (best) to 136 (worst). (NCT00158262)
Timeframe: Months 1 and 3
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Month 1 | Month 3 | |
| Placebo | 28.5 | 19.0 |
| Propranolol | 28.5 | 21.2 |
"Craving level will be measured using a 8 point Visual Analogue Scale (VAS) of craving. Participants will be ask How much do you want a cigarette right now Participants will answer accordingly: 0=no desire at all; 7=unable to resist craving" (NCT00916721)
Timeframe: Craving level was measured at visit 3, after presentation of two neutral and two smoking scripts
| Intervention | units on a scale (Mean) |
|---|---|
| Propranolol | 5.52 |
| Placebo | 4.3 |
Heart rate was measured through 9-mm (sensor diameter) Ag/AgCl electrodes filled with electrolytic paste and placed on the medial surface of each forearm. Amplified electrocardiogram signal will input to a tachometer that will provide a voltage output reflecting interbeat interval, which will be transformed to HR. A Coulbourn Modular Instrument System was used to measure HR during 4 periods; baseline, reading, imagery and recovery (NCT00916721)
Timeframe: Heart rate was measured at visit 3, after presentation of two neutral and two smoking scripts
| Intervention | beats per minute (Mean) |
|---|---|
| Propranolol | 0.877 |
| Placebo | 1.162 |
Corrugator EMG will be obtained through Ag/AgCl electrodes. The amplified EMG signal will be integrated using a 300-msec. time constant. A Coulbourn Modular Instrument System was used to measure corrugator EMG during 4 periods; baseline, reading, imagery and recovery (NCT00916721)
Timeframe: Corrugator EMG level was measured at visit 3, after presentation of two neutral and two smoking scripts
| Intervention | µV (Mean) |
|---|---|
| Propranolol | 0.479 |
| Placebo | 1.464 |
Skin conductance level was obtained through 9-mm (sensor diameter) Ag/AgCl electrodes filled with isotonic paste placed on the non-dominant hypothenar surface using a constant-voltage technique. A Coulbourn Modular Instrument System was used to measure SC during 4 periods; baseline, reading, imagery and recovery. (NCT00916721)
Timeframe: skin conductance was measured at visit 3, after presentation of two neutral and two smoking scripts
| Intervention | µS (Mean) |
|---|---|
| Propranolol | 0.107 |
| Placebo | -0.040 |
Measured in blood plasma using enzyme-linked immunosorbent assay. Log-transformed prior to analysis to correct for skew in data. Four different change scores were calculated: first, change at post-drug from pre-drug baseline; second, the change at 30-min post-stressor from post-drug baseline; third, change at 60-min post-stressor from post-drug baseline; and fourth, change at 90-min post-stressor from post-drug baseline. (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 30-min post-stressor; 60-min post-stressor; 90-min post-stressor
| Intervention | log(picograms/mL) (Mean) | |||
|---|---|---|---|---|
| Post-drug from pre-drug baseline | 30-min post-stress from post-drug baseline | 60-min post-stress from post-drug baseline | 90-min post-stress from post-drug baseline | |
| Placebo | .16 | .24 | .19 | .46 |
| Propanolol Hydrochloride | .05 | .31 | .32 | .48 |
"Self-report measure of affect (emotion) state using the Positive & Negative Affect Schedule Negative Affect (PANAS). Answered on a Likert scale from 0 (not at all) - 6 (very much). Mean score range is from 0-6. Higher numbers indicate more negative, high arousal emotions; low numbers indicate less negative, high arousal emotions. Three change scores were calculated from the four different rating measurement time points: a change in negative, high arousal emotions at the post-drug baseline from the pre-drug baseline; a change in emotions right before the Trier Social Stress Task (TSST) from the post-drug baseline; and a change in emotions during the TSST from the post-drug baseline." (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 2-min before the stressor; 1-min post-stressor
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Post-drug from pre-drug baseline | TSST-prep from post-drug baseline | TSST stressor from post-drug baseline | |
| Placebo | -.13 | .37 | .76 |
| Propanolol Hydrochloride | -.10 | .18 | .61 |
Mean level pre-ejection period (PEP; centered at zero) derived from impedance cardiography and electrocardiogram. Four different change scores were calculated: first, the change in average PEP from the 5-min pre-drug baseline to the 5-min post-drug baselines; second, the change in average PEP that occurred during the 2-min anticipatory stress speech preparation phase of the Trier Social Stress Test (TSST) from the post-drug baseline; third, the change in average PEP that occurred across the 15-min of the TSST (speech + math tasks) from the post-drug baseline; fourth and finally, the change in average PEP that occurred across 7-min in a post-stressor recovery period as compared to the post-drug baseline. (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 2-min before the stressor; 15-min during stressor, 7-min recovery post-stressor
| Intervention | milliseconds (Mean) | |||
|---|---|---|---|---|
| Post-drug from pre-drug baseline | TSST-prep from post-drug baseline | TSST from post-drug baseline | Post-stress recovery from post-drug baseline | |
| Placebo | .86 | -10.92 | -10.69 | -1.19 |
| Propanolol Hydrochloride | 7.14 | -5.33 | -.80 | .21 |
Mean level respiratory sinus arrhythmia (RSA) derived from electrocardiogram; measure of heart rate variability assessed as the ratio of low-to-high frequencies in the respiratory-cardiac power spectrum. Four different change scores were calculated: first, the change in average RSA from the 5-min pre-drug baseline to the 5-min post-drug baselines; second, the change in average RSA that occurred during the 2-min anticipatory stress speech preparation phase of the Trier Social Stress Test (TSST) from the post-drug baseline; third, the change in average RSA that occurred across the 15-min of the TSST (speech + math tasks) from the post-drug baseline; fourth and finally, the change in average RSA that occurred across 7-min in a post-stressor recovery period as compared to the post-drug baseline. (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 2-min before the stressor; 15-min during stressor, 7-min recovery post-stressor
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Post-drug from pre-drug baseline | TSST-prep from post-drug baseline | TSST from post-drug baseline | Post-stress recovery from post-drug baseline | |
| Placebo | .27 | -.43 | -.87 | -.26 |
| Propanolol Hydrochloride | .11 | .36 | -.06 | .36 |
Concentration of alpha amylase in saliva quantified quantified by enzyme kinetic method. Two different change scores were calculated: first, the pre-drug to post-drug baseline change and, second, the 15-min post-stressor change from post-drug baseline. (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 15-min post-stressor
| Intervention | picograms / mL (Mean) | |
|---|---|---|
| Post-drug from pre-drug baseline | 15-min post-stress from post-drug baseline | |
| Placebo | -6.36 | 6.73 |
| Propanolol Hydrochloride | -7.50 | -15.68 |
Concentration of cortisol in saliva quantified quantified by chemiluminescence immunoassay with high sensitivity. Three different change scores were calculated from pre-drug to post-drug baselines, 15-min post-stressor from post-drug baseline, and 30-min post-stressor from post-drug baseline. (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 15-min post-stressor; 30-min post-stressor
| Intervention | nanomole/L (Mean) | ||
|---|---|---|---|
| Post-drug from pre-drug baseline | 15-min post-stress from post-drug baseline | 30-min post-stress from post-drug baseline | |
| Placebo | -3.76 | 4.02 | 1.86 |
| Propanolol Hydrochloride | -6.42 | 5.61 | 2.1 |
21 reviews available for propranolol and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Effects of propranolol on the modification of trauma memory reconsolidation in PTSD patients: A systematic review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Fear; Humans; Memory; Propranolol; Stress Disorders, Post-Traumatic | 2022 |
Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder.
Topics: Anxiety; Anxiety Disorders; Humans; Propranolol; Stress Disorders, Post-Traumatic | 2022 |
Pharmacological memory modulation to augment trauma-focused psychotherapy for PTSD: a systematic review of randomised controlled trials.
Topics: Cycloserine; Dexamethasone; Humans; Mifepristone; Propranolol; Psychotherapy; Randomized Controlled | 2023 |
Between an ugly truth and a perfect lie: Wiping off fearful memories using beta-adrenergic receptors antagonists.
Topics: Adrenergic beta-Antagonists; Animals; Brain; Fear; Humans; Memory Consolidation; Mental Disorders; P | 2019 |
[Prophylaxis and therapy of post-traumatic stress disorder with propranolol: evidence and ethical analysis].
Topics: Adrenergic beta-Antagonists; Animals; Arousal; Combined Modality Therapy; Disease Models, Animal; Et | 2013 |
Psychopharmacological treatment for military posttraumatic stress disorder: an integrative review.
Topics: Adrenergic beta-Antagonists; Humans; Military Personnel; Propranolol; Selective Serotonin Reuptake I | 2013 |
Pharmacological modulation of acute trauma memories to prevent PTSD: considerations from a developmental perspective.
Topics: Adrenergic beta-Antagonists; Adult; Animals; Child; Humans; Hydrocortisone; Hypothalamo-Hypophyseal | 2014 |
Pharmacological interventions for preventing post-traumatic stress disorder (PTSD).
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Amines; Anti-Anxiety Agents; Anti-Inflammatory | 2014 |
Prevention of posttraumatic stress disorder with propranolol: A meta-analytic review.
Topics: Anti-Anxiety Agents; Clinical Trials as Topic; Humans; Observational Studies as Topic; Propranolol; | 2015 |
Pharmacotherapy as prophylactic treatment of post-traumatic stress disorder: a review of the literature.
Topics: Adrenergic beta-Antagonists; Drug Therapy; Humans; Hydrocortisone; Morphine; Premedication; Proprano | 2015 |
Revisiting propranolol and PTSD: Memory erasure or extinction enhancement?
Topics: Adrenergic beta-Antagonists; Animals; Behavior, Animal; Disease Models, Animal; Extinction, Psycholo | 2016 |
Neuroethics and psychiatry.
Topics: Adrenergic beta-Antagonists; Brain; Ethics, Professional; Humans; Informed Consent; Propranolol; Psy | 2008 |
Emerging treatments for PTSD.
Topics: Cognitive Behavioral Therapy; Combat Disorders; Computer Simulation; Cycloserine; Humans; Implosive | 2009 |
Preventing post traumatic stress disorder: are drugs the answer?
Topics: Anti-Anxiety Agents; Ethanol; Humans; Hydrocortisone; Morphine; Propranolol; Stress Disorders, Post- | 2010 |
Novel combination strategy to optimize treatment for PTSD.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Combat Disorders; Dru | 2011 |
Early intervention for post-traumatic stress disorder.
Topics: Cognitive Behavioral Therapy; Humans; Primary Prevention; Propranolol; Randomized Controlled Trials | 2007 |
Memory and memories.
Topics: Adrenergic beta-Antagonists; Animals; Brain; Humans; Mental Recall; Nerve Tissue Proteins; Neurons; | 2013 |
Psychopharmacology and memory.
Topics: Adrenergic beta-Antagonists; Amygdala; Brain; Cognition; CREB-Binding Protein; Emotions; Humans; Mem | 2006 |
Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic beta-Ant | 2008 |
Post-traumatic stress disorder and its treatment in children and adolescents.
Topics: Adolescent; Child; Child Abuse; Child, Preschool; Citalopram; Clinical Trials as Topic; Clonidine; C | 2008 |
Psychopharmacology. Psychopharmacological issues in posttraumatic stress disorder.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Humans; Hypnotics and Sedat | 1983 |
15 trials available for propranolol and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial.
Topics: Adrenergic beta-Antagonists; Adult; Depressive Disorder, Major; Humans; Propranolol; Stress Disorder | 2021 |
Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial.
Topics: Adrenergic beta-Antagonists; Adult; Depressive Disorder, Major; Humans; Propranolol; Stress Disorder | 2021 |
Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial.
Topics: Adrenergic beta-Antagonists; Adult; Depressive Disorder, Major; Humans; Propranolol; Stress Disorder | 2021 |
Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial.
Topics: Adrenergic beta-Antagonists; Adult; Depressive Disorder, Major; Humans; Propranolol; Stress Disorder | 2021 |
Does Acute Propranolol Treatment Prevent Posttraumatic Stress Disorder, Anxiety, and Depression in Children with Burns?
Topics: Adolescent; Adrenergic beta-Antagonists; Anxiety; Burns; Child; Depression; Female; Follow-Up Studie | 2018 |
Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Implosive Therapy; Male; Memory, Episodic; Middle Aged; | 2018 |
Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Implosive Therapy; Male; Memory, Episodic; Middle Aged; | 2018 |
Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Implosive Therapy; Male; Memory, Episodic; Middle Aged; | 2018 |
Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Implosive Therapy; Male; Memory, Episodic; Middle Aged; | 2018 |
Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Implosive Therapy; Male; Memory, Episodic; Middle Aged; | 2018 |
Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Implosive Therapy; Male; Memory, Episodic; Middle Aged; | 2018 |
Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Implosive Therapy; Male; Memory, Episodic; Middle Aged; | 2018 |
Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Implosive Therapy; Male; Memory, Episodic; Middle Aged; | 2018 |
Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Implosive Therapy; Male; Memory, Episodic; Middle Aged; | 2018 |
Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies.
Topics: Adrenergic beta-Antagonists; Adult; Arousal; Combat Disorders; Double-Blind Method; Emotions; Female | 2015 |
Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies.
Topics: Adrenergic beta-Antagonists; Adult; Arousal; Combat Disorders; Double-Blind Method; Emotions; Female | 2015 |
Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies.
Topics: Adrenergic beta-Antagonists; Adult; Arousal; Combat Disorders; Double-Blind Method; Emotions; Female | 2015 |
Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies.
Topics: Adrenergic beta-Antagonists; Adult; Arousal; Combat Disorders; Double-Blind Method; Emotions; Female | 2015 |
Propranolol's impact on cognitive performance in post-traumatic stress disorder.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Arousal; Cognition; Dose-Response Relationship, Drug | 2016 |
The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: a pilot study.
Topics: Adolescent; Adrenergic beta-Antagonists; Child; Double-Blind Method; Emergencies; Female; Humans; Li | 2010 |
Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials.
Topics: Adult; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Propranolol; Stre | 2011 |
Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Drive; Electromyography; Female; Follow-Up Stu | 2012 |
Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Drive; Electromyography; Female; Follow-Up Stu | 2012 |
Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Drive; Electromyography; Female; Follow-Up Stu | 2012 |
Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Drive; Electromyography; Female; Follow-Up Stu | 2012 |
Propranolol, traumatic memories, and amnesia: a study of 36 cases.
Topics: Adult; Amnesia; Delayed-Action Preparations; Female; Humans; Male; Memory; Propranolol; Stress Disor | 2012 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Drug Administration Schedule; Female; Human | 2003 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Admi | 2008 |
Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients.
Topics: Adolescent; Adult; Amines; Anti-Anxiety Agents; California; Cyclohexanecarboxylic Acids; Female; Gab | 2007 |
beta-Adrenergic blockade and emotional memory in PTSD.
Topics: Adrenergic beta-Antagonists; Adult; Arousal; Blood Pressure; Double-Blind Method; Emotions; Heart Ra | 2001 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.
Topics: Accidents, Traffic; Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
Effects of a specific beta 2-receptor blocker in neuroleptic-induced akathisia.
Topics: Adrenergic beta-Antagonists; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chronic Disease; | 1989 |
54 other studies available for propranolol and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Memory reconsolidation impairment using the β-adrenergic receptor blocker propranolol reduces nightmare severity in patients with posttraumatic stress disorder: a preliminary study.
Topics: Adrenergic beta-Antagonists; Dreams; Humans; Memory Disorders; Propranolol; Prospective Studies; Rec | 2022 |
Rapid and efficient treatment of post-traumatic stress disorder induced by anaesthesia awareness with recall using reconsolidation therapy.
Topics: Adrenergic beta-Antagonists; Humans; Intraoperative Awareness; Mental Recall; Propranolol; Stress Di | 2023 |
Blockade of muscarinic receptors impairs reconsolidation of older fear memory by decreasing cholinergic neurotransmission: A study in rat model of PTSD.
Topics: Adrenergic beta-Antagonists; Animals; Atropine; Conditioning, Classical; Disease Models, Animal; Fea | 2020 |
Propranolol failed to prevent severe stress-induced long-term behavioral changes in male rats.
Topics: Animals; Conditioning, Psychological; Electric Stimulation; Exploratory Behavior; Fear; Male; Propra | 2021 |
Influence of early stress on memory reconsolidation: Implications for post-traumatic stress disorder treatment.
Topics: Adrenergic beta-Antagonists; Animals; Conditioning, Classical; Corticosterone; Disease Models, Anima | 2018 |
Propranolol can induce PTSD-like memory impairments in rats.
Topics: Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Fear | 2018 |
Propranolol produces short-term facilitation of extinction in a rabbit model of post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Animals; Arousal; Blinking; Conditioning, Classical; Conditioning, Eyel | 2018 |
Eradicating Traumatic Memories: Implications for PTSD Treatment.
Topics: Humans; Memory; Mental Recall; Propranolol; Stress Disorders, Post-Traumatic | 2018 |
Myocardial hypersensitivity to ischemic injury is not reversed by clonidine or propranolol in a predator-based rat model of posttraumatic stress disorder.
Topics: Adrenergic Agents; Animals; Anxiety; Cardiovascular Agents; Clonidine; Disease Models, Animal; Disea | 2019 |
Reconsolidation of Traumatic Memories Using Psychotherapy.
Topics: Fear; Humans; Memory; Propranolol; Psychotherapy; Stress Disorders, Post-Traumatic | 2018 |
On the Use of Memory Update Mechanisms to Treat Patients: Response to Waits and Hoge.
Topics: Humans; Memory; Propranolol; Psychotherapy; Stress Disorders, Post-Traumatic | 2018 |
Reduction in the occurrence of distressing involuntary memories following propranolol or hydrocortisone in healthy women.
Topics: Adolescent; Adult; Female; Humans; Hydrocortisone; Memory; Propranolol; Secondary Prevention; Stress | 2020 |
Another look at the legal and ethical consequences of pharmacological memory dampening: the case of sexual assault.
Topics: Adrenergic beta-Antagonists; Bioethical Issues; Humans; Memory; Propranolol; Sex Offenses; Stress Di | 2013 |
Trauma reactivation plus propranolol is associated with durably low physiological responding during subsequent script-driven traumatic imagery.
Topics: Adaptation, Physiological; Adaptation, Psychological; Adrenergic beta-Antagonists; Adult; Female; He | 2014 |
Propranolol, post-traumatic stress disorder, and intensive care: incorporating new advances in psychiatry into the ICU.
Topics: Adrenergic beta-Antagonists; Critical Care; Critical Illness; Humans; Intensive Care Units; Memory; | 2014 |
Emotional face processing in post-traumatic stress disorder after reconsolidation impairment using propranolol: A pilot fMRI study.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amygdala; Emotions; Facial Expression; Fear; F | 2015 |
Enhanced noradrenergic activity in the amygdala contributes to hyperarousal in an animal model of PTSD.
Topics: Adrenergic Neurons; Amygdala; Animals; Clenbuterol; Disease Models, Animal; Electroshock; Hippocampu | 2016 |
Serotonergic Synergy in the Pharmacotherapy of Acute Posttraumatic Stress Disorder Exacerbation: A Case Report.
Topics: Adult; Antipsychotic Agents; Drug Synergism; Fear; Histamine H1 Antagonists; Humans; Hydroxyzine; Ma | 2017 |
Propranolol, post-traumatic stress disorder and narrative identity.
Topics: Adrenergic beta-Antagonists; Bioethical Issues; Humans; Memory; Narration; Patient Participation; Pr | 2008 |
Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma.
Topics: Adrenergic beta-Antagonists; Burns; Child; Female; Humans; Male; Propranolol; Risk Factors; Stress D | 2010 |
Propranolol use in the prevention and treatment of posttraumatic stress disorder in military veterans: forgetting therapy revisited.
Topics: Adrenergic beta-Antagonists; Ethics, Clinical; Humans; Memory; Memory Disorders; Military Personnel; | 2010 |
Early post-stressor intervention with propranolol is ineffective in preventing posttraumatic stress responses in an animal model for PTSD.
Topics: Adrenergic beta-Antagonists; Animals; Anxiety; Behavior, Animal; Cues; Disease Models, Animal; Heart | 2011 |
Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats--a possible mechanism for the persistence of traumatic memories in PTSD.
Topics: Acoustic Stimulation; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Amygdala; Animals; Cond | 2011 |
Remembered for forgetting.
Topics: Adrenergic beta-Antagonists; Analgesics, Opioid; Emotions; Humans; Memory Disorders; Mental Recall; | 2012 |
The change in muscarinic receptor subtypes in different brain regions of rats treated with fluoxetine or propranolol in a model of post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Amygdala; Animals; Anxiety; Blotting, Western; Brain Chemistry; Explora | 2012 |
Propranolol for reemergent posttraumatic stress disorder following an event of retraumatization: a case study.
Topics: Accidents, Traffic; Adult; Anti-Anxiety Agents; Female; Humans; Propranolol; Recurrence; Stress Diso | 2002 |
After the trauma: what doesn't help and what may.
Topics: Anti-Anxiety Agents; Cognitive Behavioral Therapy; Humans; Propranolol; Psychotherapeutic Processes; | 2003 |
Forgetting and remembering. Learning to forget.
Topics: Adrenergic beta-Antagonists; Amygdala; Animals; Bioethical Issues; Brain; Extinction, Psychological; | 2004 |
Conceptually driven pharmacologic approaches to acute trauma.
Topics: Adaptation, Psychological; Adrenergic alpha-Agonists; Adrenergic Antagonists; Adult; Amygdala; Anima | 2005 |
Beta-blockers tackle memories of horror.
Topics: Adrenergic beta-Antagonists; Animals; Clinical Trials as Topic; Fear; Humans; Male; Memory; Neurotra | 2005 |
Effects of beta blockade, PTSD diagnosis, and explicit threat on the extinction and retention of an aversively conditioned response.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arousal; Association Learning; Combat Disorders; Condition | 2006 |
Noradrenergic signaling in the amygdala contributes to the reconsolidation of fear memory: treatment implications for PTSD.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Fear; Humans; Memory; Norepinephrine; Propranolol; Rats; Sig | 2006 |
Toward a new treatment for traumatic memories.
Topics: Animals; Extinction, Psychological; Humans; Memory; Neurosciences; Propranolol; Psychopharmacology; | 2006 |
Involvement of noradrenergic and corticoid receptors in the consolidation of the lasting anxiogenic effects of predator stress.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Associatio | 2007 |
Perspectives on memory manipulation: using beta-blockers to cure post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Animals; Bioethics; Emotions; Humans; Memory; Propranolol; Rats; Stress | 2007 |
Healing trauma: finding treatments that work.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anti-Anxiety Agents; Combat Disorders; Ev | 2007 |
Response to open commentaries for "Propranolol and the prevention of post-traumatic stress disorder: is it wrong to erase the 'sting' of bad memories?".
Topics: Adrenergic beta-Antagonists; Bioethical Issues; Humans; Memory; Propranolol; Stress Disorders, Post- | 2007 |
Propranolol and the prevention of post-traumatic stress disorder: is it wrong to erase the "sting" of bad memories?
Topics: Adrenergic beta-Antagonists; Advisory Committees; Bioethical Issues; Ethics Committees; Humans; Memo | 2007 |
Spinoza's Passions.
Topics: Adrenergic beta-Antagonists; Bioethical Issues; History, 17th Century; Humans; Memory; Mind-Body Rel | 2007 |
Debunking alarmist objections to the pharmacological prevention of PTSD.
Topics: Adrenergic beta-Antagonists; Bioethical Issues; Humans; Memory; Propranolol; Stress Disorders, Post- | 2007 |
Clarifying the debate over therapeutic forgetting.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Bioethical Issues; Ethics Committees; Humans; Memo | 2007 |
Necessary forgetting: on the use of propranolol in post-traumatic stress disorder management.
Topics: Adrenergic beta-Antagonists; Bioethical Issues; Humans; Memory; Propranolol; Stress Disorders, Post- | 2007 |
Preventing post-traumatic stress disorder or pathologizing bad memories?
Topics: Adrenergic beta-Antagonists; Bioethical Issues; Humans; Memory; Propranolol; Stress Disorders, Post- | 2007 |
Propranolol, cognitive biases, and practical decision-making.
Topics: Adrenergic beta-Antagonists; Bioethical Issues; Cognition; Decision Making; Humans; Memory; Proprano | 2007 |
Emotions, memory suppression, and identity.
Topics: Adrenergic beta-Antagonists; Bioethical Issues; Emotions; Humans; Memory; Propranolol; Self Concept; | 2007 |
The moral costs of prophylactic propranolol.
Topics: Adrenergic beta-Antagonists; Bioethical Issues; Crime; Humans; Memory; Morals; Propranolol; Stress D | 2007 |
Propranolol and its potential inhibition of positive post-traumatic growth.
Topics: Adaptation, Psychological; Adrenergic beta-Antagonists; Bioethical Issues; Humans; Propranolol; Stre | 2007 |
Neuroethical concerns about moderating traumatic memories.
Topics: Adrenergic beta-Antagonists; Bioethical Issues; Conscience; Humans; Memory; Morals; Propranolol; Str | 2007 |
Memory-altering drugs: shifting the paradigm of informed consent.
Topics: Adrenergic beta-Antagonists; Bioethical Issues; Humans; Informed Consent; Memory; Propranolol; Stres | 2007 |
On moralizing and hidden agendas: the pot and the kettle in political bioethics.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Bioethical Issues; Ethics Committees; Humans; Memo | 2007 |
[Prevention of stress disorders of myocardial contractile function using membrane protectors].
Topics: Animals; Calcium; Chloroquine; Fatty Acids; Humans; Lipase; Myocardial Contraction; Myocardium; Niac | 1983 |
Beta blocker inhibits tricyclic metabolism.
Topics: Adrenergic beta-Antagonists; Aggression; Anger; Antidepressive Agents, Tricyclic; Child; Depressive | 1994 |
Can post-traumatic stress disorder be put on hold?
Topics: Adrenergic beta-Antagonists; Animals; Cognitive Behavioral Therapy; Humans; Memory; Propranolol; Str | 1999 |
Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study.
Topics: Child; Child Abuse; Child Abuse, Sexual; Female; Humans; Male; Propranolol; Stress Disorders, Post-T | 1988 |